1
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37:1777-1784. [PMID: 37113040 DOI: 10.1111/jdv.19134] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/29/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF). OBJECTIVES The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF). METHODS In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data. RESULTS The 122 analysed patients (69 SS, 53 MF) were aged 66.6 ± 12.1 years at mogamulizumab initiation, and their median disease duration was 2.5 years (IQR: 1.3-5.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2-5). Overall, 77.8% of patients suffered from advanced disease (Stage IIB-IVB), with frequent blood (B1/B2) involvement (67.5%). Over the treatment period (median: 4.6 months, 2.1-7.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9-68.1]) overall, 69.5% [56.1-80.8] in SS and 46.0% [31.8-60.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1-90.9] of SS patients. Skin responses were observed in 57.0% [47.0-66.5] of patients overall, 66.7% [52.9-78.6] in SS and 46.0% [31.8-60.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion-related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab-related tumour lysis syndrome. CONCLUSIONS This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.
Collapse
Affiliation(s)
- M Beylot-Barry
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - G Quereux
- Dermatology Department, Nantes University Hospital, University of Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, CHU Besancon, Besancon, France
- INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - A-B Duval-Modeste
- Department of Dermatology, INSERM U519, Rouen University Hospital, Rouen, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - S Dalac-Rat
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
- Department of Dermatology, HTCC, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - A Pham-Ledard
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M D'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - F Grange
- Department of Dermatology, Valence Hospital, Valence, France
| | - V Braniste
- Kyowa Kirin Pharma, Medical Affairs, Neuilly-sur-Seine, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
2
|
Rothenbuhler A, Gueorguieva I, Lichtenberger-Geslin L, Audrain C, Soskin S, Bensignor C, Rossignol S, Bertholet-Thomas A, Naudeau L, Bacchetta J, Linglart A. Young XLH Patients-Reported Experience with a Supportive Care Program. Patient Prefer Adherence 2023; 17:1393-1405. [PMID: 37325587 PMCID: PMC10263015 DOI: 10.2147/ppa.s391025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 05/03/2023] [Indexed: 06/17/2023] Open
Abstract
Purpose X-linked hypophosphatemia (XLH) is a rare, chronic, genetic condition characterized by renal phosphate wasting and abnormal bone and teeth mineralization. It represents a challenging and multifaceted disease that causes wide-ranging impacts on patients' lives. In this context, a scientific committee has designed a support initiative for patients treated for XLH: the aXess program. We sought to determine if a patient support program (PSP) could help XLH patients cope with their condition. Methods During the 12 months of participation in the aXess program, XLH patients were contacted by phone by a nurse to coordinate their treatment, ensure treatment adherence, and provide motivational interviews. A Pediatric QOL inventory was conducted on all participants at enrollment (D0), at month 6, and month 12. Results Altogether, a total of 59 patients were enrolled in the program. Most patients reported an improvement in QOL in all examined dimensions by month 12 (physical, emotional, social, and school, 85.4 ± 0.2 at month 12 versus 75.6 ± 0.3 at enrollment, p<0.05). Patients were very satisfied with the program, with a mean overall satisfaction score of 9.8 ± 0.6 (on a scale from 0 to 10) at month 6 and 9.2 ± 1.5 at month 12. Conclusion Our findings indicate that this program might improve the QOL for patients with chronic conditions such as XLH through patient education, therapy adherence, motivational interviews, and frequent follow-up. It links the home environment and overall illness management, bringing patients, families, and caregivers together.
Collapse
Affiliation(s)
- Anya Rothenbuhler
- AP-HP, INSERM, Endocrinology and Diabetes for Children, Physiologie et Physiopathologie Endocriniennes, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Filière OSCAR, and Platform of Expertise for Rare Disorders, ERN for Rare Endocrine Disorders and ERN BOND, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
| | - Iva Gueorguieva
- Pediatric Endocrine Unit Children’s Hospital Jeanne de Flandre, Lille University Hospital, Lille, France
| | | | - Christelle Audrain
- AP-HP, INSERM, Endocrinology and Diabetes for Children, Physiologie et Physiopathologie Endocriniennes, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Filière OSCAR, and Platform of Expertise for Rare Disorders, ERN for Rare Endocrine Disorders and ERN BOND, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
| | - Sylvie Soskin
- Pediatric Department, Strasbourg University Hospital, Strasbourg, France
| | - Candace Bensignor
- Departement of Endocrino-Pediatry, Dijon University Hospital, Dijon, France
| | - Sylvie Rossignol
- Pediatric Department, Strasbourg University Hospital, Strasbourg, France
| | - Aurélia Bertholet-Thomas
- Pediatric Nephrology, Rheumatology, and Dermatology Unit, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, Reference Center for Rare Renal Diseases, Filières Maladies Rares OSCAR ORKiD and ERK-Net, INSERM 1033, Hôpital Femme Mère Enfant, Faculté de Médecine Lyon Est, Bron, France
| | | | - Justine Bacchetta
- Pediatric Nephrology, Rheumatology, and Dermatology Unit, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, Reference Center for Rare Renal Diseases, Filières Maladies Rares OSCAR ORKiD and ERK-Net, INSERM 1033, Hôpital Femme Mère Enfant, Faculté de Médecine Lyon Est, Bron, France
| | - Agnès Linglart
- AP-HP, INSERM, Endocrinology and Diabetes for Children, Physiologie et Physiopathologie Endocriniennes, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Filière OSCAR, and Platform of Expertise for Rare Disorders, ERN for Rare Endocrine Disorders and ERN BOND, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
- Paris Saclay University, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
| |
Collapse
|